Subjective well-being and quality of life under atypical antipsychotic treatment

Psychopharmacology

Volumn 162, Issue 1, 2002, Pages 3-10

  Karow, A ^a   Naber, D ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Atypical neuroleptic; Quality of life; Review; Schizophrenia; Subjective well being

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZOTEPINE;

AKINESIA; ALERTNESS; ANHEDONIA; CLINICAL TRIAL; COGNITION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; EMOTIONAL STABILITY; FITNESS; HUMAN; HUMAN RELATION; MENTAL DISEASE; METHODOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REST; REVIEW; SCHIZOPHRENIA; SEXUALITY; SLEEP; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIOLOGY; SYMPTOMATOLOGY; TREATMENT OUTCOME; WELLBEING; HEALTH PROMOTION; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; STATISTICS;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HEALTH PROMOTION; HUMAN; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; HUMANS;

EID: 0035987326     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1052-z     Document Type: Review

References (59)

1. A sociological perspective on health-related quality of life research
2. Pharmacological differention of classical and novel antipsychotics
3. Characterizing quality of life among patients with chronic mental illness: A critical examination of the self-report methodology
4. Subjective response to neuroleptics in schizophrenics
5. Subjective response to neuroleptics and the quality of life: Implications for treatment outcome
6. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride
7. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation
8. Measuring quality of life in patients with schizophrenia
9. The Sickness Impact Profile: Development and final revision of a health status measure
10. Quality of life in schizophrenia
11. Quality of life in schizophrenia: Long-term follow-up in 362 chronic spanish schizophrenic outpatients undergoing risperidone maintenance treatment
12. Quality of life and disability in chronic schizophrenics treated with risperidone and previously treated with deport neuroleptics
13. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization
14. Rehabilitation programmes and quality of life in severe mental illness
15. Quality of life in schizophrenia: Insight and subjective response to neuroleptics
16. Generic quality of life assessment in psychiatry. Potentials and limitations
17. Evaluating quality-of-life measures for clinical trials in Germany
18. Quality of life in cancer patients - An hypothesis
19. Symptoms, standards of living and subjective quality of life: A comparative study of schizophrenic and depressed out-patients
20. Motor and mental aspects of extrapyramidal syndromes
21. Measurement of therapeutic response in schizophrenia. A critical survey
22. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
23. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
24. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
25. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
26. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients
27. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center
28. A critical appraisal of the quality of quality-of-life measurements
29. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial
30. Psychometrische Testung der "Münchener Lebensqualitäts Dimensionen Liste (MLDL)"
31. The quality of life scale: An instrument for rating the schizophrenic deficit scale
32. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia
33. A self report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
34. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia
35. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia
36. Subjective exprience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics
37. The well-being of chronic mental patients: Assessing their quality of life
38. Neuroleptics and the neuroleptic-induced deficit syndrome
39. Evaluation of the quality of life of the schizophrenic outpatient: A checklist
40. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
41. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
42. Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients
43. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
44. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia
45. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Quality of life and clinical outcomes of a randomized clinical trial
46. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
47. Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives
48. Deficit symptoms in schizophrenia: Negative symptoms versus neuroleptic-induced deficits
49. Comparison of quality of life with standard of living in schizophrenic out-patients
50. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
51. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaf-fective and schizophreniform disorders: Results of an international collaborative trial
52. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
53. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol
54. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point
55. Subjective response to antipsychotic drugs
56. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability
57. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
58. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection